FDA announced the Rare Disease Framework Initiative, a new effort to reimagine how drugs and biologics for rare diseases are developed and reviewed.

The initiative was outlined in a newly released white paper and is expected to build an optimized, fit-for-purpose regulatory framework that accounts for the nuances of each disease, patient needs, product type and the evidence that can realistically be generated in small patient populations.^1,2

The agency will be hosting a public meeting on October 28 at its White Oak campus to gather feedback on the initiative from patients and disease advocates, industry representatives and other stakeholders.¹The meeting will be facilitated by the Reagan-Udall Foundation for FDA.

Why is FDA pursuing this now?

FDA has relied on regulatory flexibility and targeted programs to support rare disease drug development; efforts the agency says have produced meaningful advances for both patients and families. Despite that, only about 5% of rare conditions currently have an FDA-approved treatment, a gap the agency says underscores the need for a more tailored approach.¹ The agency says it agrees with patients, drug developers, and providers, saying that more must be done to accelerate development of safe and effective treatments for this population.^1,2

In building the new framework, FDA is committing to several priorities:

• Providing greater clarity, consistency and predictability in regulatory decision-making through tailored guidance and transparent communication.
• Embedding the patient’s voice early and at defined milestones throughout the drug development and review process.
• Further leveraging external expertise to support customized regulatory review.
• Building shared resources, training and institutional knowledge on rare disease drug development and review.
• Applying risk-based approaches, particularly to chemistry, manufacturing, and controls review along with pre-approval inspections.
• Championing cutting-edge science, novel methods, and innovative statistical approaches in rare disease drug development.

The Initiative is led by FDA’s Rare Disease Innovation Hub, in partnership with the Office of the Commissioner, the Center for Biologics Evaluation, and Research and the Center for Drug Evaluation and Research.^1,2

What are officials saying about the effort?

Health and Human Services leadership frames the Initiative as a shift toward patient-centered regulation. “Americans with rare diseases cannot afford a regulatory system that treats every condition the same,” says Robert F. Kennedy, Jr., HHS secretary. “Under President Trump, FDA is rethinking rare disease drug development by putting patients at the center and matching regulatory requirements to the realities of small patient populations. We will remove unnecessary barriers, embrace cutting-edge science, and accelerate promising treatments while upholding FDA’s rigorous standards.”

Acting FDA Commissioner Kyle Diamantas, J.D., emphasizes the agency’s intent to modernize its approach while preserving existing standards. “Patients and families living with rare diseases have few or no approved treatment options, and the burden of uncertainty can extend across every part of their lives,” he says. “As we learn more about rare diseases and better understand the breadth of suffering they cause, we must ensure that America’s regulatory system remains at the forefront — prepared to respond to emerging science, anticipate the needs of patients and families, and help bring safe and effective therapies to those who need them. FDA will fight hard for patients by building a more consistent, predictable, and innovative approach to rare disease drug development while maintaining the rigorous standards Americans expect from FDA.”

What happens after the October meeting?

FDA says additional opportunities for stakeholder input will follow the public meeting, including sector-specific roundtables, requests for information and internal feedback sessions.¹ That input will inform the detailed development of the new framework, which could include new or revised guidance, changes to regulations, staff training and organizational changes within the agency.

Sources

1. FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development U.S. Food and Drug Administration October 14, 2026, https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease
2. A New Framework for Rare Disease Review U.S. Food and Drug Administration October 14, 2026, https://www.fda.gov/media/195694/download?attachment